What is the Optimal Duration of Treatment for DVT? An Update on Evidence-Based Medicine of Treatment for DVT

East, Andrea T.; Wakefield, Thomas W.

doi:10.1053/j.semvascsurg.2010.05.006

Cited by 25 publications

(15 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several reviews [94–96], meta-analyses, and systematic reviews of the literature [97–100] have focused on this issue.…”

Section: Risk Factors For Recurrencementioning

confidence: 99%

Recurrent Venous Thromboembolism: What Is the Risk and How to Prevent It

Palareti¹

2012

Scientifica

View full text Add to dashboard Cite

Venous thromboembolism (VTE) that includes deep vein thrombosis and/or pulmonary embolism is a frequent, severe, and potentially lethal disease. After a first episode, VTE has a strong tendency to recur. While VTE is an acute disease, it may have variable outcomes in early and late phases after initial presentation. Furthermore, the incidence of late, clinically important consequences (postthrombotic syndrome and/or chronic thromboembolic pulmonary hypertension) increases in case of recurrent events. The aims of the present review are (i) to analyze the incidence and risk factors for recurrence of VTE (either those related to the type of first thrombotic event or to the patients), the risks associated with occurrence of recurrent events, and the problems linked to the diagnosis, not always easy, of recurrent events; (ii) to discuss whether or not it is possible to predict the individual risk of recurrence after a first event, by stratifying patients at high or low risk of recurrence, and how this can influence their treatment; (iii) to comment what the current guidelines and guidance suggest/recommend about anticoagulant treatment after a first VTE event and, finally, to propose practical indications on how to manage individual patients affected by VTE.

show abstract

“…Several reviews [94–96], meta-analyses, and systematic reviews of the literature [97–100] have focused on this issue.…”

Section: Risk Factors For Recurrencementioning

confidence: 99%

Recurrent Venous Thromboembolism: What Is the Risk and How to Prevent It

Palareti¹

2012

Scientifica

View full text Add to dashboard Cite

show abstract

“…Thrombophilias, especially hereditary, and those with positive family history are known risks for DVT complications. 56 Due to small numbers and limited reports examining thrombophilia in C-DVT cases, its relationship with calf vein thrombi complications could not be determined by this review. However, other interesting aspects of recurrence under investigation include d-dimer levels 57 and residual thrombosis on ultrasonography, 58 both of which may prove to be important predictors of recurrence and guide duration of anticoagulation.…”

Section: Discussionmentioning

confidence: 93%

The controversy of managing calf vein thrombosis

Masuda

Kistner²,

Musikasinthorn

et al. 2012

Journal of Vascular Surgery

132

View full text Add to dashboard Cite

No study of strong methodology could be found to resolve the controversy of optimal treatment of C-DVT. Given the risks of propagation, PE, and recurrence, the option of doing nothing should be considered unacceptable. In the absence of strong evidence to support anticoagulation over imaging surveillance with selective anticoagulation, either method of managing calf DVT must remain as current acceptable standards.

show abstract

“…Furthermore, unfractionated or low-molecular-weight heparin (LMWH) is used for at least five days, and, simultaneously, oral anticoagulation with a vitamin K antagonist (VKA) is initiated. LMWH is stopped when the international normalised ratio (INR) has been within the therapeutic level of 2.0-3.0 for at least two days [2, 5]. The risk of recurrent venous thromboembolism (VTE) is highest during the first 6 to 12 months, but oral VKA can be expected to decrease recurrence rate to about 1% per year [5].…”

Section: Introductionmentioning

confidence: 99%

“…LMWH is stopped when the international normalised ratio (INR) has been within the therapeutic level of 2.0-3.0 for at least two days [2, 5]. The risk of recurrent venous thromboembolism (VTE) is highest during the first 6 to 12 months, but oral VKA can be expected to decrease recurrence rate to about 1% per year [5]. The duration of VKA treatment is usually 3–12 months and is based on an individual estimate of recurrence and bleeding risk [4].…”

Section: Introductionmentioning

confidence: 99%

Cardiac Arrest Caused by Multiple Recurrent Pulmonary Embolism

Hannig

Husted

Grove

2011

Case Reports in Medicine

View full text Add to dashboard Cite

Pulmonary embolism is a common condition with a high mortality. We describe a previously healthy 68-year-old male who suffered three pulmonary embolisms during a short period of time, including two embolisms while on anticoagulant treatment. This paper illustrates three important points. (1) The importance of optimal anticoagulant treatment in the prevention of pulmonary embolism reoccurrence. (2) The benefit of immediate accessibility to echocardiography in the handling of haemodynamically unstable patients with an unknown underlying cause. (3) Thrombolytic treatment should always be considered and may be life-saving in patients with cardiac arrest suspected to be caused by pulmonary embolism.

show abstract

What is the Optimal Duration of Treatment for DVT? An Update on Evidence-Based Medicine of Treatment for DVT

Cited by 25 publications

References 46 publications

Recurrent Venous Thromboembolism: What Is the Risk and How to Prevent It

Recurrent Venous Thromboembolism: What Is the Risk and How to Prevent It

The controversy of managing calf vein thrombosis

Cardiac Arrest Caused by Multiple Recurrent Pulmonary Embolism

Contact Info

Product

Resources

About